Acroscell, the mature division of Creative Bioarray, is dedicated to developing top-quality products and cutting-edge technologies for the academia, pharmaceutical, and biotechnology industries. As a service company with strong strength in the field of electrophysiological techniques, Acroscell focused on both in vivo and in vitro assays to satisfy the needs in electrophysiological analysis, from single channel analysis to moving animals. Recently, Acroscell announced the release of its
cardiac ion channel screen panels to detect and analyze the effects of candidate drugs.
Creative Bioarray has developed a GLP-compliant in vitro electrophysiological service, providing customers with a powerful ion channel platform from which the mechanism of action and safety of lead compounds can be characterized. This in vitro cardiac profile screening provides a comprehensive safety analysis, including inhibition testing and IC 50 indicators.
By evaluating its ability to block hERG channels in vitro and prolong the QTc interval of ventricular repolarization and ECG, it effectively eliminated the risk of approving drugs that may produce TdP in patients. With traditional patch-clamp and MEA technology, Creative Bioarray can provide services to detect and analyze the effects of drug candidates on key cardiac ion channels and pathways, and provide predictable and repeatable data. Creative Bioarray now offers a cardiac safety panel test to determine the interaction of the drug with the cardiac ion channel that is the target of QT prolongation, which can help minimize unnecessary classification of promising compounds.
Creative Bioarray provides manual and automatic patch clamp function assays to evaluate the inhibitory or enhancing effects of drugs on Kv4.3 channels. In this assay, HEK293-Kv4.3 cells are used to specifically evaluate the effects of test compounds. In Creative Bioarray, Kv4.3 analysis is included in the provided CiPA service package. For specific target screening, the team provides manual or automatic patch clamp recording services to determine the drug impact on Kv4.3. For the needs of testing potential Kv4.3 drug targets, Creative Bioarray can provide customized projects.
The hERG safety test provided by Creative Bioarray complies with ICH S7B guidelines, and many other ion channel inhibition tests are also available. In addition, professional scientists have developed an automated QPatch-HT system to provide better consistency at a lower cost. Creative Bioarray can also utilize traditional whole-cell patch clamp detection, and the supported cell types include CHO-hERG cells or HEK293-hERG cells.
“Creative Bioarray has a comprehensive cell bank, which contains a variety of specialized and unique stable cell lines expressing ion channels, which can be immediately applied to various in vitro studies and in vivo pharmacological studies.” said Hannah Cole, the marketing director of Creative Bioarray, she also added, “Creative Bioarray is committed to meeting all your needs in electrophysiological analysis. We provide customers with a full range of research at every step of their drug discovery research.”